Clinical trial
A Phase II, Multicenter, Single-Blind, Randomized Study of the Safety and Effectiveness of SANGUINATE™ Versus Normal Saline in Adult Sickle Cell Disease Patients With Vaso-Occlusive Crisis (VOC)
NCT02672540 is registered in ClinicalTrials.gov with Prolong Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Multicenter, Single-Blind, Randomized Study of the Safety and Effectiveness of SANGUINATE™ Versus Normal Saline in Adult Sickle Cell Disease Patients With Vaso-Occlusive Crisis (VOC)
- Lead sponsor
- Prolong Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2016
- Completion date
- May 31, 2017
- Enrollment
- 34 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.